| El Paso Health & Rehabilitation Center | |
| 11525 Vista Del Sol Dr, El Paso, Texas 79936 | |
| (915) 855-3636 | |
| Name | El Paso Health & Rehabilitation Center |
|---|---|
| Location | 11525 Vista Del Sol Dr, El Paso, Texas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 130 |
| Occupancy Rate | 66.85% |
| Medicare ID (CCN) | 455935 |
| Legal Business Name | El Paso Snf Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1124352901 |
| Organization Name | WEST WHARTON COUNTY HOSPITAL DISTRICT |
| Doing Business As | EL PASO HEALTH & REHABILITATION CENTER |
| Address | 11525 Vista Del Sol Dr, El Paso, TX 79936 |
| Phone Number | 915-855-3636 |
News Archive
AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
All too often women with eating disorders cannot recognise they have a problem, or go to great lengths to disguise the problem from others.
What's a guy to do? While prostate specific antigen (PSA) testing has been the standard screening tool for prostate cancer for several decades, results of a study recently published in The New England Journal of Medicine question the effectiveness of PSA screening in reducing death from prostate cancer. But many urologists argue that men should not be swayed from getting the test-it still saves lives.
Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
› Verified 8 days ago
| NPI Number | 1497158927 |
| Organization Name | ECTOR COUNTY HOSPITAL DISTRICT |
| Doing Business As | EL PASO HEALTH AND REHABILITATION CENTER |
| Address | 11525 Vista Del Sol Drive, El Paso, TX 79936 |
| Phone Number | 915-855-3636 |
News Archive
AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
All too often women with eating disorders cannot recognise they have a problem, or go to great lengths to disguise the problem from others.
What's a guy to do? While prostate specific antigen (PSA) testing has been the standard screening tool for prostate cancer for several decades, results of a study recently published in The New England Journal of Medicine question the effectiveness of PSA screening in reducing death from prostate cancer. But many urologists argue that men should not be swayed from getting the test-it still saves lives.
Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
› Verified 8 days ago
| NPI Number | 1780674473 |
| Organization Name | EL PASO OPERATIONS HEALTHCARE CENTER, L.P. |
| Doing Business As | EL PASO HEALTH & REHABILITATION CENTER |
| Address | 11525 Vista Del Sol Dr, El Paso, TX 79936 |
| Phone Number | 915-855-3636 |
News Archive
AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
All too often women with eating disorders cannot recognise they have a problem, or go to great lengths to disguise the problem from others.
What's a guy to do? While prostate specific antigen (PSA) testing has been the standard screening tool for prostate cancer for several decades, results of a study recently published in The New England Journal of Medicine question the effectiveness of PSA screening in reducing death from prostate cancer. But many urologists argue that men should not be swayed from getting the test-it still saves lives.
Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
All too often women with eating disorders cannot recognise they have a problem, or go to great lengths to disguise the problem from others.
What's a guy to do? While prostate specific antigen (PSA) testing has been the standard screening tool for prostate cancer for several decades, results of a study recently published in The New England Journal of Medicine question the effectiveness of PSA screening in reducing death from prostate cancer. But many urologists argue that men should not be swayed from getting the test-it still saves lives.
Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 24.28 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.6 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 63.92 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.66 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.68 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.66 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.23 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.73 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 36.98 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.06 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.66 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.62 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 70.61 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 91.22 | 82.93 |
News Archive
AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
All too often women with eating disorders cannot recognise they have a problem, or go to great lengths to disguise the problem from others.
What's a guy to do? While prostate specific antigen (PSA) testing has been the standard screening tool for prostate cancer for several decades, results of a study recently published in The New England Journal of Medicine question the effectiveness of PSA screening in reducing death from prostate cancer. But many urologists argue that men should not be swayed from getting the test-it still saves lives.
Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
› Verified 8 days ago
Mountain View Health & Rehabilitation Location: 1600 Murchison Rd, El Paso, Texas 79902 Phone: (915) 544-2002 | |
Pebble Creek Nursing Center Location: 11608 Scott Simpson Dr, El Paso, Texas 79936 Phone: (817) 348-8959 | |
El Paso Health & Rehabilitation Center Location: 11525 Vista Del Sol Dr, El Paso, Texas 79936 Phone: (915) 855-3636 | |
Good Samaritan Society--white Acres Location: 7304 Good Samaritan Ct, El Paso, Texas 79912 Phone: (915) 581-4683 |